111 Inc (YI)
NASDAQ:YI
Want to see YI full AI Analyst Report?
YI Stock Chart & Stats
$2.85
-$0.01(-2.07%)
At close: 4:00 PM EST
$2.85
-$0.01(-2.07%)
Day’s Range― - ―
52-Week Range$2.48 - $11.17
Previous CloseN/A
Volume1.06M
Average Volume (3M)22.80K
Market Cap
$50.08M
Enterprise Value-$6.96M
Total Cash (Recent Filing)$447.47M
Total Debt (Recent Filing)$212.93M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.56
Shares Outstanding5,067,436
10 Day Avg. Volume15,490
30 Day Avg. Volume22,804
Financial Highlights & Ratios
PEG Ratio6.95
Price to Book (P/B)-0.22
Price to Sales (P/S)0.01
P/FCF Ratio1.36
Enterprise Value/Market Cap-0.14
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda23.52
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)$17.20B
Bulls Say, Bears Say
Bulls Say
Improved Cash GenerationThe shift to positive operating and free cash flow in 2024–2025 materially improves near-term self-funding. Durable cash generation reduces reliance on equity/debt raises, supports working capital and execution of strategic initiatives, and provides a runway to solidify operational recovery.
Asset-light Operational PivotMoving to an asset-light model with exclusive fulfillment partners reduces fixed assets and capex needs, improving operating leverage and scalability. By outsourcing logistics the company lowers structural opex and can sustain margin expansion if volume stabilizes, a lasting structural efficiency gain.
Improved Liquidity PositionA larger cash buffer and positive operating cash flow strengthen short-term liquidity and reduce immediate refinancing pressure. This improvement increases flexibility to invest in digital initiatives, support partners, and absorb near-term volatility while management executes the operational pivot.
Bears Say
Declining Revenue TrendPersistent top-line decline erodes scale advantages in distribution and retail, weakening bargaining power with suppliers and partners. Lower volumes make fixed-cost absorption harder, threatening long-term margin gains and forcing continued cost-cutting or asset sales to protect profitability.
Very Thin Gross MarginsSub-6% gross margins leave limited room to cover SG&A and invest in growth. The business remains highly sensitive to supplier pricing, logistics costs, or volume declines, meaning margin improvements from efficiency are fragile and profitability could reverse with modest adverse shifts.
Pressured Balance SheetNegative shareholder equity and meaningful debt constrain financial flexibility and heighten recapitalization or dilution risk. Declining total assets and distorted leverage metrics limit the company's ability to finance growth or withstand shocks without external funding, a durable constraint.
111 News
YI FAQ
What was 111 Inc’s price range in the past 12 months?
111 Inc lowest stock price was $2.48 and its highest was $11.17 in the past 12 months.
What is 111 Inc’s market cap?
111 Inc’s market cap is $50.08M.
When is 111 Inc’s upcoming earnings report date?
111 Inc’s upcoming earnings report date is Aug 20, 2026 which is in 86 days.
How were 111 Inc’s earnings last quarter?
Currently, no data Available
Is 111 Inc overvalued?
According to Wall Street analysts 111 Inc’s price is currently Overvalued.
Does 111 Inc pay dividends?
111 Inc does not currently pay dividends.
What is 111 Inc’s EPS estimate?
111 Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 111 Inc have?
111 Inc has 5,067,436 shares outstanding.
What happened to 111 Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of 111 Inc?
Currently, no hedge funds are holding shares in YI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
111 Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.24%
12-Months-Change
Fundamentals
Return on Equity
8.26%
Trailing 12-Months
Asset Growth
-17.56%
Trailing 12-Months
Company Description
111 Inc
111, Inc. operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2B and B2C. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services that include online consultation services and electronic prescription services to consumers. It offers prescription and over-the counter drugs, including western and traditional Chinese medicines; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices comprising bandages and thermometers; and personal care products consisting of skin care, birth control, and sexual wellness products; and baby products. The company also operates an online marketplace where third-party sellers can directly sell to pharmacies; provides online loan application services to the clients of 1 Pharmacy, which include pharmacies and wholesalers; and data and supply chain integration services. As of December 31, 2021, it operated 14 offline retail pharmacies under the Yi Hao Pharmacy brand name in Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan provinces. In addition, the company offers warehousing, logistics, procurement, research and development, and consulting services; and software development and information technology support services. It serves pharmacies, pharmaceutical companies and distributors, medical professionals, and insurance companies. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.
Technical Analysis
Rockwell Med
―
Dyadic International
―
Rein Therapeutics
―
Elutia
―
Neuphoria Therapeutics
―
Ownership Overview
59.73% Insiders
0.05% Mutual Funds
0.09% Other Institutional Investors
40.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---